Close Menu

NEW YORK (GenomeWeb) – Researchers plan to develop a gut microbiome signature of nonalcoholic fatty liver disease-linked cirrhosis into a diagnostic test for the condition.

Between 20 percent and 30 percent of US adults have nonalcoholic fatty liver disease (NAFLD), a condition in which excess fat is stored in the liver, according to the National Institute of Diabetes and Digestive and Kidney Diseases. It's more common among people with obesity and type 2 diabetes and can lead to cirrhosis, which is itself a risk factor for liver cancer.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

Sponsored by
LGC SeraCare Life Sciences

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.

Sponsored by

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.